Negative symptoms and neurocognition in drug-naïve schizophrenia: moderating role of plasma neutrophil gelatinase-associated lipocalin (NGAL) and interferon-gamma (INF-γ)
Authors:
- 25 July 2023
- journal article
- research article
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (5) , 1071-1081
Abstract
Previous studies reported that peripheral inflammation was associated with cognitive performance and brain structure in schizophrenia. However, the moderating effect of inflammation has not been extensively studied. This study investigated whether inflammation markers moderated the association between negative symptoms and neurocognition in schizophrenia. This cross-sectional study included 137 drug-naïve schizophrenia patients (DNS) and 67 healthy controls (HC). We performed the Measurements and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) for cognitive assessment and the Positive and Negative Syndrome Scale (PANSS) for psychiatric symptoms. Plasma concentrations of interferon-gamma (IFN-γ), neutrophil gelatinase-associated lipocalin (NGAL), and nuclear factor kappa B (NF-κB) were measured. The MCCB neurocognition score, social cognition score, and total score; the plasma concentrations of NGAL, IFN-γ, and NF-κB were significantly decreased in DNS than in HC (all P’s < 0.001). PANSS negative subscale (PNS), PANSS reduced expressive subdomain (RES) negatively correlated with neurocognition score (P = 0.007; P = 0.011, respectively). Plasma concentrations of IFN-γ and NGAL positively correlated with neurocognition score (P = 0.043; P = 0.008, relatively). The interactions of PNS × NGAL; PNS × IFN-γ; RES × IFN-γ accounted for significant neurocognition variance (P = 0.025; P = 0.029, P = 0.007, respectively). Simple slope analysis showed that all the above moderating effects only occurred in patients with near normal IFN-γ and NGAL levels. Plasma concentrations of IFN-γ and NGAL moderated the relationship between negative symptoms (especially RES) and neurocognition in schizophrenia. Treatment targeting inflammation may contribute to neurocognition improvement in schizophrenia.Keywords
Funding Information
- Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-033A)
- Tianjin Key Medical Discipline (Specialty) Construction Project of Tianjin Health Commission (TJWJ2022XK039)
- Foundation of Tianjin Health Commission for Young Scholars (KJ20067)
- Natural Science Foundation of Tianjin Municipal Science and Technology Commission (22JCZDJC00110)
This publication has 89 references indexed in Scilit:
- Neutrophil gelatinase-associated lipocalin: A new antioxidant that exerts its cytoprotective effect independent on Heme Oxygenase-1Free Radical Research, 2011
- A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase SchizophreniaThe Journal of Clinical Psychiatry, 2009
- Determinants of everyday outcomes in schizophrenia: The influences of cognitive impairment, functional capacity, and symptomsSchizophrenia Research, 2009
- Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in SchizophreniaNeuropsychopharmacology, 2009
- The Interaction of Nuclear Factor-Kappa B and Cytokines Is Associated with SchizophreniaBiological Psychiatry, 2009
- Neutrophil Gelatinase-associated Lipocalin Acts as a Protective Factor against H2O2 ToxicityArchives of Medical Research, 2008
- Monocytic, Th1 and Th2 Cytokine Alterations in the Pathophysiology of SchizophreniaNeuropsychobiology, 2007
- Neutrophil granules: a library of innate immunity proteinsTrends in Immunology, 2007
- Treatment of cognitive dysfunction in schizophreniaClinical Therapeutics, 2005
- Cognitive function in schizophreniaPsychiatric Clinics of North America, 2003